Regulatory & Legal

Following a $25M fundraise, former WA Health Secretary Dr. Shah joins Jaan Health, signaling a new era for AI-driven chronic disease management.

As cyber threats in healthcare escalate, CIVIE's HITRUST e1 certification signals a new standard for patient data protection in AI-driven medical tech.

The AI security firm regained reporting compliance, but a critical hearing and debt talks will decide its fate as it battles to stay on the exchange.

A new industry group aims to build trust in state-linked stablecoins by setting standards for disclosure and redemption, but is it self-regulation or a prelude to law?

Austrian firm AOP Health secures nationwide access for its rapid heart rate drug, Rapiblyk™, by partnering with top US distributors. What does this mean for critical care?

Unrivaled's renewed partnership with Mount Sinai isn't just a deal; it's a statement on player health, setting a new benchmark for women's pro sports.

Orrstown Financial Advisors is opening a dedicated 4,000 sq. ft. office, signaling a strategic push to enhance client service in a growing regional market.

Inogen reports modest growth and a pivotal return to positive EBITDA, yet a revenue miss from delayed B2B orders raises questions for its turnaround.

With a new board member and strategic investment, Kandu, Inc. is set to scale its brain-computer interface technology for stroke recovery.

A new study reveals payment failures cost billions as customer patience runs out in minutes, creating a crisis for retail and hospitality brands.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

Leasing begins at The Orchard, a new luxury giant in Long Island City. But as it sets records, it also raises questions about the neighborhood's future.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

A new White House executive order and a proposed $1.5T budget are shaking up defense contracting. Here's how agile firms like Volatus are set to win.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

As FuelCell Energy eyes larger global projects, it hires a legal expert known for scaling power giants, signaling a strategic shift to execution.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.